TGF-B RECEPTOR GENE MUTATIONS DETECTED IN HUMAN CANCER
TGF-B RECEPTOR GENE MUTATIONS DETECTED IN HUMAN CANCER
批准号:
2733292
负责人:
SANFORD D. MARKOWITZ
金额:
$40.37万
依托单位国家:
美国
项目类别:
财政年份:
1996
资助国家:
美国
项目状态:
已结题
起止时间:
1996-09-01 至 2001-06-30
关键词:
athymic mouse biological signal transduction carcinogenesis clinical research colon neoplasms epithelium gastrointestinal neoplasms gene mutation growth factor receptors human subject immunoprecipitation monoclonal antibody mutant neoplasm /cancer diagnosis neoplasm /cancer genetics neoplastic growth nucleic acid repetitive sequence pathologic process phenotype polymerase chain reaction tissue /cell culture transforming growth factors tumor suppressor genes uterus neoplasms western blottings
中文摘要
这一建议的目标是阐明自然发生的人类之间
英文摘要
The goal of this proposal is to elucidate among naturally occurring human
malignancies novel molecular defects that inactivate the TGF-beta pathway
of tumor suppression. Recent investigations by our group of
collaborators have identified the TGF-beta receptor as a new member of
the tumor suppressor gene family and have shown that TGF-beta receptor
gene mutation is important in the pathogenesis of certain colon cancers.
TGF-beta inhibits the growth of many epithelial cell types and for
example both abolishes growth of and induces apoptosis in nontransformed
colon epithelial cells. In contrast, colon and many other cancer cell
lines are resistant to TGF-beta growth suppression. Our recent studies
have demonstrated TGF-beta resistance in one group of colon cancers is
due to the inactivation by somatic mutation of the type II component
(RII) of the TGF-beta receptor complex. Moreover, we have shown that
correcting, by RII gene transfer, the RII mutations in such colon cancer
cells abolishes the cells capacity to form tumors. The TGF-beta receptor
is thus a novel tumor suppressor whose inactivation directly contributes
to carcinogenesis. The TGF-beta receptor is composed of a heterodimeric
complex of type I (RI) and type II (RII) subunits. In model systems,
mutation of either RI or RII inactivates the receptor complex and confers
TGF-beta resistance. The hypothesis of this proposal is that most
cancers escape TGF-beta growth control by mutation of the RII component
of the TGF-beta receptor, mutation of the type RI component of the TGF-
beta receptor, or mutation of downstream components of the TGF-beta
signalling pathway.
We initially identified RII mutations predominantly within a ten base
pair polyadenine repeat (BAT-RII) present in the RII coding sequence and
also identified these mutations as characteristic only of those colon
cancers that also demonstrated the genetic defect of microsatellite
instability (RER colon cancers). The RER phenotype is characteristic of
colon, endometrial and gastric cancers that arise with high incidence in
kindreds with the Hereditary Nonpolyposis Colon Cancer familial cancer
syndrome. RER is also present in many cancers of the proximal (right
sided) colon, the endometrium and the stomach arising among individuals
in the general population who do not belong to cancer families.
Recently, we have now identified in some RER colon cancers added novel
(not BAT-RII) sites of RII mutation. Most recently, we have also
identified among NonRER colon cancer the first case that bears a novel
site of RII mutation, and an added case that is the first to likely bear
a mutation in post-RII elements of the TGF-beta signalling pathway. The
specific aims of this proposal will now determine: i) how these novel
mutations functionally inactive TGF-beta signalling; ii) how commonly
TGF-beta resistance contributes to carcinogenesis among NonRER colon
cancers; iii) how often TGF-beta resistance in NonRER colon cancers is
mediated by RII mutations, by RI mutations, or by defects in post
receptor components of the TGF-beta signalling pathway; iv) the role of
BAT-RII mutations in the genesis of RER cancers characteristic of certain
noncolonic tissues (stomach and endometrium), as well as whether NonRER
gastric and endometrial cancers, like NonRER colon cancers, bear
additional novel mutations that inactivate TGF-beta signalling. Lastly,
we will determine whether a diagnostic test for BAT-RII mutations will
allow early detection in man of RER colon cancers.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Chemical, Structural and Cell-Signaling Interrogation of 15-Prostanglandin Dehydrogenase in Tissue Repair and Regeneration
-
批准号:10627860
-
项目类别:
-
资助金额:$135.45万
-
财政年份:2021
-
负责人:SANFORD D. MARKOWITZ
-
依托单位:
Targeting 15-Prostaglandin Dehydrogenase (15-PGDH) in Cancer Risk, Prevention, and Treatment
-
批准号:9406781
-
项目类别:
-
资助金额:$95.1万
-
财政年份:2016
-
负责人:SANFORD D. MARKOWITZ
-
依托单位:
Targeting 15-Prostaglandin Dehydrogenase (15-PGDH) in Cancer Risk, Prevention, and Treatment
-
批准号:10524057
-
项目类别:
-
资助金额:$93.2万
-
财政年份:2016
-
负责人:SANFORD D. MARKOWITZ
-
依托单位:
Targeting 15-Prostaglandin Dehydrogenase (15-PGDH) in Cancer Risk, Prevention, and Treatment
-
批准号:10305660
-
项目类别:
-
资助金额:$93.2万
-
财政年份:2016
-
负责人:SANFORD D. MARKOWITZ
-
依托单位:
Targeting 15-Prostaglandin Dehydrogenase (15-PGDH) in Cancer Risk, Prevention, and Treatment
-
批准号:9183207
-
项目类别:
-
资助金额:$95.1万
-
财政年份:2016
-
负责人:SANFORD D. MARKOWITZ
-
依托单位:
Targeting 15-Prostaglandin Dehydrogenase (15-PGDH) in Cancer Risk, Prevention, and Treatment
-
批准号:10058813
-
项目类别:
-
资助金额:$95.1万
-
财政年份:2016
-
负责人:SANFORD D. MARKOWITZ
-
依托单位:
Role of gene enhancer elements in colon cancer
-
批准号:8449075
-
项目类别:
-
资助金额:$38.26万
-
财政年份:2012
-
负责人:SANFORD D. MARKOWITZ
-
依托单位:
Role of gene enhancer elements in colon cancer
-
批准号:8289140
-
项目类别:
-
资助金额:$39.4万
-
财政年份:2012
-
负责人:SANFORD D. MARKOWITZ
-
依托单位:
Role of gene enhancer elements in colon cancer
-
批准号:8633432
-
项目类别:
-
资助金额:$39.48万
-
财政年份:2012
-
负责人:SANFORD D. MARKOWITZ
-
依托单位:
Case GI SPORE
-
批准号:8528379
-
项目类别:
-
资助金额:$215.05万
-
财政年份:2011
-
负责人:SANFORD D. MARKOWITZ
-
依托单位:
Targeting 15-PGDH in Colon Cancer Prognosis, Prediction, Treatment and Prevention
-
批准号:8555227
-
项目类别:
-
资助金额:$41.97万
-
财政年份:2011
-
负责人:SANFORD D. MARKOWITZ
-
依托单位:
Administrative Core
-
批准号:10706702
-
项目类别:
-
资助金额:$66.48万
-
财政年份:2011
-
负责人:SANFORD D. MARKOWITZ
-
依托单位:
Case GI SPORE
-
批准号:8332751
-
项目类别:
-
资助金额:$225.03万
-
财政年份:2011
-
负责人:SANFORD D. MARKOWITZ
-
依托单位:
Case GI SPORE
-
批准号:8711319
-
项目类别:
-
资助金额:$216.2万
-
财政年份:2011
-
负责人:SANFORD D. MARKOWITZ
-
依托单位:
Case GI SPORE
-
批准号:10227747
-
项目类别:
-
资助金额:$232.5万
-
财政年份:2011
-
负责人:SANFORD D. MARKOWITZ
-
依托单位:
Case GI SPORE
-
批准号:10704292
-
项目类别:
-
资助金额:$66.48万
-
财政年份:2011
-
负责人:SANFORD D. MARKOWITZ
-
依托单位:
Project 1: Targeting 15-PGDH in Colon Cancer Risk, Prevention and Treatment
-
批准号:10227752
-
项目类别:
-
资助金额:$23.25万
-
财政年份:2011
-
负责人:SANFORD D. MARKOWITZ
-
依托单位:
Administrative Core
-
批准号:10227748
-
项目类别:
-
资助金额:$23.25万
-
财政年份:2011
-
负责人:SANFORD D. MARKOWITZ
-
依托单位:
Case GI SPORE
-
批准号:8918463
-
项目类别:
-
资助金额:$218.5万
-
财政年份:2011
-
负责人:SANFORD D. MARKOWITZ
-
依托单位:
Case GI SPORE
-
批准号:9753939
-
项目类别:
-
资助金额:$232.5万
-
财政年份:2011
-
负责人:SANFORD D. MARKOWITZ
-
依托单位:
海外基金